Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence (AdV-VANTAGE)

This study has been terminated.
(Strategic reasons. Seeking partner for future development.)
Sponsor:
Information provided by:
Ark Therapeutics Ltd
ClinicalTrials.gov Identifier:
NCT00895479
First received: May 7, 2009
Last updated: November 18, 2010
Last verified: November 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: September 2011
  Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)